Faculty

Institution

Unit

Venue

Naifa Lamki Busaidy

Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Clinical Cancer Genetics

Department Of Endocrine Neoplasia And Hormonal Disorders

Department Of Endocrine Neoplasia And Hormonal Disorders And The Children'S Cancer Hospital

The University of Texas MD Anderson Cancer Center

Naifa Lamki Busaidy is a Professor at The University of Texas MD Anderson Cancer Center. Her research focuses on thyroid oncology, specifically the treatment of anaplastic thyroid carcinoma (ATC) and radioiodine-refractory disease. She investigates combination therapies, including lenvatinib with pembrolizumab, and the cardiac toxicities of BRAF/MEK inhibitors. Her recent work includes systematic reviews on whole-brain radiation for thyroid cancer brain metastases and NCCN guidelines for thyroid carcinoma. She collaborates internationally through the International Thyroid Oncology Group, contributing to redifferentiation therapy strategies.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Naifa Lamki Busaidy

The University of Texas MD Anderson Cancer Center

Professor

You can click a keyword to filter the displayed items

oncology thyroid thyroid disease radiation oncology cancer research pharmacology cancer treatment medicine tumor biology endocrine oncology surgical oncology oncogenes endocrinology urology medicinal research therapeutic targets cancer care molecular cancer cancer biology cancer immunotherapy clinical research anaplastic thyroid carcinoma endocrine-related cancers parathyroid disease thyroid cancer cancer genomics thyroid hormone anti-cancer agents cancer cells cancer management cancer discovery parathyroid glands cancer imaging gynecologic oncology cancer genetics pharmacotherapy anaplastic thyroid cancer parathyroid carcinoma clinical trials cellular therapy neck oncology leukemia medical mycology tumor targeting clinical radiation oncology radiation therapy parathyroid hormone nuclear medicine vascular biology thyroid carcinoma immune checkpoint inhibitors tumor heterogeneity adrenal disease novel therapies oncogenic agent clinical mycology tumoral pathology differentiated thyroid cancer clinical case presentation therapeutic efficacy endocrine research targeted therapy medullary thyroid cancer treatment and prevention comparative endocrinology cancer growth endocrine surgery tyrosine kinase inhibitors advanced cancer primary hyperparathyroidism medullary thyroid carcinoma cancer-related fatigue overall survival clinical outcomes adrenocortical carcinoma liver cancer

Notable Scholarly Works

Notable Federal Grants

Collaborators

26-A-11351-Acc Braf and Mek Inhibitors in Thyroid Cancer and the Heart: Tracking the Incidence of Cardiac Dysfunction and Heart Failure. Journal of the American College of Cardiology (2026)

cardiovascular toxicityoncogenescardiovascular researchpathologyradiation oncologyheart failurethe heartmolecular cancerpharmacologycancer treatmentthyroidoncology

Deceptive Thyroid Pathologies: Anaplastic Thyroid Carcinoma Mimics and Clinical Implications. Head & Neck (2026)

thyroidendocrine oncologydeceptive thyroid pathologiesthyroid disease

Palliative Neck Radiation Therapy (Rt) in Combination With Lenvatinib/Pembrolizumab (L/P) in Braf Wild-Type Anaplastic Thyroid Cancer (Braf-Wt Atc).. Journal of Clinical Oncology (2026)

clinical radiation oncologyradiation therapyradiation oncologyneck oncologythyroid diseasethyroidoncology

Real-World Experience With Lenvatinib Plus Pembrolizumab in Metastatic Braf Wild-Type Anaplastic Thyroid Carcinoma. Thyroid (2026)

metronomic therapymetastasispathologyradiation oncologyreal-world experiencemolecular cancerthyroid diseasecancer treatmentthyroidoncology

Whole-Brain Radiation Therapy for Brain Metastases Due to Thyroid Cancer: A Systematic Review and Meta-Analysis. Clinical Oncology (2026)

whole-brain radiation therapyneurologymetastasisradiation oncologyradiation therapybrain tumor researchthyroid diseasethyroid cancerbrain metastasesradiationthyroidoncologyneuro-oncology

Abstract 4358317: Emergence of Hypertension in Thyroid Cancer Patients on Braf ± Mek Inhibitors: A Closer Look at Incidence and Contributing Risk Factors. Circulation (2025)

tumor biologyoncologymolecular cancerthyroid diseasethyroid cancer patientscontributing risk factorsantihypertensive therapymedicinepharmacologytherapeutic targetsabstract 4358317thyroidhypertension

Abstract 4756: Novel Anaplastic Thyroid Carcinoma Patient-Derived Xenograft Models and Cell Line. Cancer Research (2025)

oncogenespathologycell linetumor biologyendocrine oncologycell biologymolecular cancerthyroid diseasecancer researchcancer cellsthyroidoncologyabstract 4756

Abstract Lb414: Characterization of the Genomic Landscape of Braf -, Ras -, and Fusion-Negative Thyroid Carcinomas Underscores the Role of Tumor Suppressor Genes. Cancer Research (2025)

oncogenespathologygenomic landscapetumor biologycancer biologycell biologymolecular cancerthyroid diseasecarcinogenesismolecular diagnosticstumor suppressorscancer geneticscancer genomicstumor suppressor genescancer letterthyroidabstract lb414genetics

Adjuvant Pembrolizumab After Upfront Multimodal Therapy for Stage Ivb Anaplastic Thyroid Cancer. Thyroid (2025)

pathologyradiation oncologycancer immunotherapythyroid diseaseadjuvant pembrolizumabimmune checkpoint inhibitorsjama oncologymedicineupfront multimodal therapycancer treatmentthyroidoncology

Characterization of Advanced Ras -Driven Follicular-Derived Thyroid Cancers and Review of Future Therapeutic Avenues. The Journal of Clinical Endocrinology & Metabolism (2025)

oncogenesradiation oncologytumor biologycancer immunotherapycell biologymolecular cancerthyroid diseasecarcinogenesiscancer researchcancer discoverycancer cellscancer letterthyroidtumor microenvironmentfuture therapeutic avenues

1
2
3
4
5
22
10 / page

Naifa Lamki Busaidy

Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Clinical Cancer Genetics

Department Of Endocrine Neoplasia And Hormonal Disorders

Department Of Endocrine Neoplasia And Hormonal Disorders And The Children'S Cancer Hospital

The University of Texas MD Anderson Cancer Center

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Naifa Lamki Busaidy

The University of Texas MD Anderson Cancer Center

Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

26-A-11351-Acc Braf and Mek Inhibitors in Thyroid Cancer and the Heart: Tracking the Incidence of Cardiac Dysfunction and Heart Failure. Journal of the American College of Cardiology (2026)

cardiovascular toxicityoncogenescardiovascular researchpathologyradiation oncologyheart failurethe heartmolecular cancerpharmacologycancer treatmentthyroidoncology

Deceptive Thyroid Pathologies: Anaplastic Thyroid Carcinoma Mimics and Clinical Implications. Head & Neck (2026)

thyroidendocrine oncologydeceptive thyroid pathologiesthyroid disease

Palliative Neck Radiation Therapy (Rt) in Combination With Lenvatinib/Pembrolizumab (L/P) in Braf Wild-Type Anaplastic Thyroid Cancer (Braf-Wt Atc).. Journal of Clinical Oncology (2026)

clinical radiation oncologyradiation therapyradiation oncologyneck oncologythyroid diseasethyroidoncology

Real-World Experience With Lenvatinib Plus Pembrolizumab in Metastatic Braf Wild-Type Anaplastic Thyroid Carcinoma. Thyroid (2026)

metronomic therapymetastasispathologyradiation oncologyreal-world experiencemolecular cancerthyroid diseasecancer treatmentthyroidoncology

Whole-Brain Radiation Therapy for Brain Metastases Due to Thyroid Cancer: A Systematic Review and Meta-Analysis. Clinical Oncology (2026)

whole-brain radiation therapyneurologymetastasisradiation oncologyradiation therapybrain tumor researchthyroid diseasethyroid cancerbrain metastasesradiationthyroidoncologyneuro-oncology

Abstract 4358317: Emergence of Hypertension in Thyroid Cancer Patients on Braf ± Mek Inhibitors: A Closer Look at Incidence and Contributing Risk Factors. Circulation (2025)

tumor biologyoncologymolecular cancerthyroid diseasethyroid cancer patientscontributing risk factorsantihypertensive therapymedicinepharmacologytherapeutic targetsabstract 4358317thyroidhypertension

Abstract 4756: Novel Anaplastic Thyroid Carcinoma Patient-Derived Xenograft Models and Cell Line. Cancer Research (2025)

oncogenespathologycell linetumor biologyendocrine oncologycell biologymolecular cancerthyroid diseasecancer researchcancer cellsthyroidoncologyabstract 4756

Abstract Lb414: Characterization of the Genomic Landscape of Braf -, Ras -, and Fusion-Negative Thyroid Carcinomas Underscores the Role of Tumor Suppressor Genes. Cancer Research (2025)

Adjuvant Pembrolizumab After Upfront Multimodal Therapy for Stage Ivb Anaplastic Thyroid Cancer. Thyroid (2025)

pathologyradiation oncologycancer immunotherapythyroid diseaseadjuvant pembrolizumabimmune checkpoint inhibitorsjama oncologymedicineupfront multimodal therapycancer treatmentthyroidoncology

Characterization of Advanced Ras -Driven Follicular-Derived Thyroid Cancers and Review of Future Therapeutic Avenues. The Journal of Clinical Endocrinology & Metabolism (2025)

1
2
3
4
5
22
10 / page